Full-Time

Field Reimbursement Manager

Migraine

Confirmed live in the last 24 hours

Axsome Therapeutics Inc

Axsome Therapeutics Inc

201-500 employees

Develops therapies for CNS disorders

Compensation Overview

$130k - $165k/yr

+ Bonus + Equity

Senior, Expert

Detroit, MI, USA

Candidates must live in their assigned geography (Detroit, MI).

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Sales
Requirements
  • Bachelor’s Degree required; graduate degree preferred
  • Minimum of 8 years of healthcare, field customer, and/or account management experience in the pharmaceutical industry with a minimum of 2 years as an FRM or RAM working specifically with retail medications (preferably with neurology experience)
  • Must live in the territory’s geography
  • Ability to travel up to 50-75% required, which may include overnight travel
Responsibilities
  • Function as a consultant to customers and staff regarding payer policies and processes (i.e., eligibility and benefit verification, prior authorization, and appeals/denials) supporting patient access to Axsome Therapeutics migraine product
  • Educate office staff on the prior authorization process, denial and appeal options, and financial support options for migraine product
  • Proactively engage with assigned accounts supporting internal/external customer access needs and compliantly engage within assigned geography to support access and adherence needs
  • Ability to develop strong relationships with customers by understanding their needs and delivering solutions to overcome obstacles
  • Expert on Axsome Therapeutics patient support programs, payer utilization management, access issue resolution, and financial assistance
  • Collaborate effectively with Managed Markets and Sales to address access challenges and issues
  • Communicate access concerns and issues with relevant internal stakeholders, including Managed Market
  • Develop and keep updated knowledge of the local and national payer landscape
  • Proficient in both virtual and live customer engagements
  • Communicate territory activity in an accurate and timely manner as directed by management
  • Assist in educating sales colleagues on product access and patient support programs, as needed
  • Complete all training classes
  • Complete administrative duties in an accurate and timely fashion
  • Effectively collaborate across all corporate functions
  • Overnight travel as indicated by the needs of the business
  • All reimbursement activities must be conducted and managed within all appropriate legal and regulatory guidelines and require continuous monitoring of compliance with such guidelines and laws
  • Additional responsibilities as assigned
Desired Qualifications
  • CNS/migraine experience strongly preferred
  • Previous experience working in an entrepreneurial environment with launch experience is preferred
  • Pharmacy benefit knowledge required, identifying, and educating to payer criteria for prior authorization
  • Knowledge and understanding of payer segments (e.g., Commercial, Medicare Part D) required
  • Experience strategizing within cross-functional teams, utilizing differential resources to achieve business goal
  • Ability to successfully manage multiple tasks concurrently under aggressive timelines in a dynamic environment
  • Demonstrated experience delivering outstanding result
  • Comfortability with uncertainty and lofty expectation
  • Ability to work independently, manage travel schedules, and schedule visits (territory management)
  • Proficient in both virtual and live customer engagement
Axsome Therapeutics Inc

Axsome Therapeutics Inc

View

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, agitation from Alzheimer's, migraines, narcolepsy, fibromyalgia, and smoking cessation. Their main product, AXS-05, is an oral medication that acts as an NMDA receptor antagonist to help regulate mood. It has shown positive results in clinical trials and has received FDA Breakthrough Therapy Designation, which speeds up its development process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and clinical trials. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

Company Size

201-500

Company Stage

IPO

Headquarters

New York City, New York

Founded

2012

Simplify Jobs

Simplify's Take

What believers are saying

  • Axsome's expansion in NYC supports growth and operational capacity by December 2025.
  • $570 million credit facility with Blackstone strengthens financial stability and flexibility.
  • Positive Phase 3 results for AXS-05 and AXS-12 boost market confidence.

What critics are saying

  • Increased competition from Sage Therapeutics and Biogen in CNS disorder treatments.
  • Potential regulatory delays could impact drug approval timelines and market entry.
  • Financial strain from NYC expansion could affect resource allocation and operations.

What makes Axsome Therapeutics Inc unique

  • Axsome focuses on CNS disorders, addressing unmet medical needs in this area.
  • AXS-05, an NMDA receptor antagonist, is a flagship product for depression treatment.
  • FDA Breakthrough Therapy Designation expedites AXS-05's development and review process.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company Equity

Company News

EMPR
Jun 10th, 2025
Symbravo Now Available for the Acute Treatment of Migraine

Axsome Therapeutics announces availability of Symbravo(R) (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults.

Intelligence360
Jun 3rd, 2025
Axsome Therapeutics Plans 96,000 Sq.Ft. Expansion In New York City.

Axsome Therapeutics plans 96,000 Sq.Ft. expansion in New York City. Axsome Therapeutics plans 96,000 Sq.Ft. expansion in New York City.New York, New York — According to state and local development sources, Axsome Therapeutics plans to build out 96,000 square feet of new space in New York. The company plans to occupy the new space in New York, on or about December 1, 2025. According to the company website Axsome Therapeutics, Inc

Stock Titan
May 13th, 2025
Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone

Axsome Therapeutics (NASDAQ: AXSM) has secured a $570 million term loan and revolving credit facility with Blackstone, replacing its previous Hercules Capital term loan. The facility consists of a $500 million term loan and a $70 million revolving credit facility. The company initially drew $120 million to retire its previous loan.The new facility offers improved terms, including interest rates of SOFR plus 4.75% for the term loan and SOFR plus 4.0% for the revolving credit facility, with a 60-month interest-only period and maturity in May 2030. Additionally, Blackstone purchased $15 million of Axsome common stock at $107.14 per share. The company can access an additional $250 million at its option, with another $200 million available subject to Blackstone's approval.

Life Care News
May 1st, 2025
Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month

NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) - Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it is joining with Mental Health America (MHA) and the broader mental health advocacy community in a consolidated effort to raise awareness and promote action during May's Mental Health Month.

Clival
Apr 8th, 2025
Axsome to Present Positive Phase 3 AXS-05 & AXS-12 Results at AAN 2025

Axsome Therapeutics, Inc., a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, announced multiple presentations spanning its innovative, industry-leading psychiatry and neurology portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting, being held April 5-9 in San Diego, California.